What is Sarepta's latest dividend and current dividend yield?

What guidance did Sarepta's management provide for the next earnings period?

What factors drove the changes in Sarepta's revenue and profit?

What is the market's earnings forecast for Sarepta next quarter?

What is Sarepta's gross profit margin?

Did Sarepta beat or miss consensus estimates last quarter?

What does Sarepta do and what are its main business segments?

What were the key takeaways from Sarepta’s earnings call?

- **Financial Resilience**: $954M cash, 2026 net product revenue guidance $1.2B-$1.4B, and positive cash flow driven by PMOs and ELEVIDYS.
- **ELEVIDYS Reset**: 2026 revenue potential $500M+ if educational campaigns succeed; 70%+ ambulatory patients untreated.
- **Pipeline Breakthroughs**: siRNA programs for DM1, FSHD, and Huntington's advancing; Phase I/II data expected Q2 2026.
- **Leadership Transition**: Doug Ingram retiring by end-2026; Board prioritizing patient-focused successor.
- **Japan Expansion**: $40M milestone payment Q1 2026 from Roche on first ELEVIDYS sale in Japan.


**【CEO Summary Section】**
- **Three Pillars of Strength**: Financial stability ($954M cash), four approved therapies (PMOs and ELEVIDYS), and a robust siRNA pipeline targeting rare diseases.
- **2026 Guidance**: Net product revenue $1.2B-$1.4B, driven by ELEVIDYS ($500M+ potential) and stable PMO franchise. Q1 2026 revenue expected flat to down 15% from Q4 2025 due to delayed infusions.
- **ELEVIDYS Reset**: $1.2B low end reflects current demand; $1.4B high end assumes successful educational campaigns. 1,200+ patients treated, but >70% ambulatory population remains untreated.
- **Pipeline Momentum**: siRNA programs for DM1, FSHD, Huntington's, and IPF advancing; Phase I/II data expected Q2 2026. Huntington's trial dosing begins Q1 2026.
- **Leadership Transition**: Doug Ingram to retire by end-2026 due to family health needs; Board initiating CEO search.

**【CFO Financial Commentary】**
- **2025 Financials**: Total revenue $2.2B (16% YoY growth), net product revenue $1.86B. GAAP operating loss $700M, non-GAAP loss $492M, but underlying business generated $330M+ cash flow.
- **Gross Margin**: 2025 unit-driven margins ~80%; 2026 expected 70%+ due to lower ELEVIDYS production. Q4 2025 cost of sales $399M (includes $193M inventory/write-off charges).
- **Expense Management**: 2026 non-GAAP R&D/SG&A guidance $800M-$900M (down from $1.85B 2025), driven by cost reductions and Arrowhead collaboration exit.
- **Japan Launch**: $40M milestone payment Q1 2026 from Roche on first ELEVIDYS sale in Japan.

**【Q&A Highlights】**
- **ELEVIDYS Dynamics**: 2026 initiatives focus on educating physicians/patients on 3-year EMBARK data (70%+ disease progression slowing). Early signals: 25% new sites submitting enrollment forms, but 6-month lag to infusion impacts Q1 guidance.
- **siRNA Pipeline**: DM1/FSHD Phase I/II data (safety, PK, early PD) expected Q2; Huntington's trial dosing begins Q1. FDA may require sirolimus prophylaxis for non-ambulatory ELEVIDYS trials.
- **PMO Competition**: Dyne's exon 51 therapy potential competitor, but Sarepta's decade of PMO data and 90%+ patient compliance provide differentiation.
- **Newborn Screening**: DMD added to federal newborn screening panel; long-term opportunity to treat younger patients, but label expansion needed for ELEVIDYS (currently 4+ years old).
- **Succession Plan**: Board evaluating internal/external candidates; focus on patient-centric leader to execute pipeline and commercial strategy.


Sarepta Therapeutics, Inc.(SRPT)-20260226-2025 Q4 Earnings call transcript

- **ESSENCE Trial Update**: 30% disease progression reduction in COVID-free patients, with real-world data showing 3-year delay in loss of ambulation.
- **FDA Confidence**: Likely acceptance of 0.09 p-value, with totality of evidence supporting continued PMO authorization.
- **Financial Resilience**: Q3 revenue $399M, $865M cash, and $500M ELEVIDYS floor for ambulatory patients.
- **Pipeline Momentum**: siRNA trials advancing, with DM1 and FSHD data expected Q1 2026.

**【CEO Summary Section】**
- Completed the ESSENCE trial for VYONDYS and AMONDYS, missing statistical significance but showing a 30% reduction in disease progression in COVID-free patients.
- Highlighted real-world evidence showing a 3-year delay in loss of ambulation and 70% reduction in mortality for PMOs.
- Plans to submit totality of evidence to FDA for traditional approval and schedule a meeting by end of 2025.
- ELEVIDYS net product revenue $131M, with 90% patient adherence and no new safety signals.
- Launched sirolimus prophylaxis study for non-ambulatory patients, aiming to resume dosing in 2026.

**【CFO Financial Commentary】**
- Q3 2025 total revenue $399M (GAAP), including $370M in product revenue and $29M in collaboration income.
- Incurred $41M restructuring charge, reducing R&D and SG&A expenses by $300M midpoint vs. prior guidance.
- Cash and investments increased to $865M, with positive cash flow and deferred manufacturing commitments.
- Advanced siRNA pipeline with DM1 and FSHD trials enrolling, targeting Q1 2026 data release.

**【Q&A Highlights】**
- FDA likely to accept 0.09 p-value for ESSENCE due to rare disease challenges, with real-world evidence supporting continued authorization.
- ELEVIDYS demand resilient despite Q3 disruptions, with $500M annual floor for ambulatory patients.
- Sirolimus study design finalized, with enrollment expected to begin soon and data in H2 2026.
- PMO franchise remains stable, with EXONDYS MISSION dose-ranging study set to read out in 2026.

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 net product revenue $612M (+70% YoY), driven by ELEVIDYS ($375M, +180%). 
- **Guidance Adjustment**: 2025 net product revenue $2.3-$2.6B (37% midpoint growth) due to: 
  - 1-1.5x longer administrative cycle times 
  - 60% revenue concentrated in fully booked top sites 
  - Q2 revenue ~20% below Q1 post safety event. 
- **Safety Profile**: 800+ patients infused, no new safety signals. FDA label update expected Q4 2025. 
- **Pipeline Momentum**: LGMD 2E BLA Q4 2025, FSHD1/DM1 data H2 2025.

**【CEO Summary Section】**
- Q1 2025 total net product revenue: $612 million (70% YoY growth). ELEVIDYS revenue: $375 million (180% YoY growth). PMO franchise: $237 million (5% YoY growth). 
- Revised 2025 guidance: $2.3-$2.6 billion net product revenue (37% midpoint growth). ELEVIDYS growth constrained by: 
  1. Administrative delays (1-1.5x longer cycle times) 
  2. Site capacity imbalance (60% of revenue from fully booked top sites) 
  3. Safety event impact (Q2 revenue ~20% below Q1)
- Emphasized ELEVIDYS' safety profile: 800+ patients infused, no new safety signals, 100% payer access maintained.

**【CFO Financial Commentary】**
- Q1 2025 GAAP net loss: $448 million (-$4.60/share). Non-GAAP net loss: $332 million (-$3.42/share). 
- R&D expenses: $773 million (includes $584 million Arrowhead collaboration upfront costs). 
- Cash position: $647 million (down $825 million for Arrowhead collaboration). 
- 2025 non-GAAP R&D/SG&A guidance: $1.2-$1.3 billion (closer to low end). 
- Maintain $900 million PMO franchise guidance.

**【Q&A Key Themes】**
1. **ELEVIDYS Safety Event**: 
   - 1 patient death (acute liver failure) out of 800+ infused. No correlation to age/weight/dose. 
   - FDA label update expected Q4 2025. No new safety signals identified. 
   - 20% Q2 revenue decline vs Q1, but "green shoots" of start forms resuming. 
2. **Commercial Challenges**: 
   - Administrative delays (Medi-Cal resolved, but systemic 1-1.5x longer cycle times). 
   - Site capacity imbalance (60% revenue from fully booked top sites). 
   - Patient education campaign underway with elevidys.com. 
3. **Pipeline Updates**: 
   - LGMD 2E (SRP-9003) BLA submission Q4 2025. 
   - FSHD1 and DM1 siRNA programs expect data readouts H2 2025. 
   - ENVISION confirmatory trial last patient last visit 2027.


Sarepta Therapeutics (SRPT)-6 May 25-2025 Q1 Earnings call transcript

- **Record Q3 revenue growth**: 12% YoY to $12.3B, driven by 18% cloud services surge.
- **$10B buyback announced**: Signals confidence amid macro volatility.
- **AI R&D supercharged**: $2B FY24 allocation for next-gen AI chips.
- **Strong margin expansion**: Operating margin +200bps to 18.5%.
- **FY24 outlook bullish**: +10% revenue growth, +12% EPS growth.

**【CEO Opening Remarks】**
- Highlighted Q3 revenue of $12.3B (+12% YoY), driven by 18% growth in cloud services and 10% increase in hardware sales.
- Announced $10B share buyback program to return capital to shareholders amid macro uncertainty.
- Emphasized AI R&D investment, with $2B allocated to next-gen AI chip development in FY24.

**【CFO Financial Breakdown】**
- GAAP EPS of $1.25 vs. $1.10 consensus; Non-GAAP EPS $1.42 (+15% YoY).
- Operating margin improved 200bps to 18.5% due to 8% YoY cost optimization.
- Free cash flow $3.2B, up 12% YoY, with $1.8B used for buybacks/Q3.

**【Q&A Key Themes】**
1. **AI Chip Supply Chain**: 12-month lead times expected to ease in H2FY24; 80%+ of Q3 AI orders fulfilled.
2. **Cloud Pricing**: 5% price increase in Q3, 70%+ customers locked into multi-year contracts.
3. **China Market**: Q3 revenue down 5% YoY, but 10% QoQ improvement; gov't partnerships to expand HPC adoption.
4. **FY24 Guidance**: Revenue $48-50B (mid +10% YoY); Non-GAAP EPS $4.80-5.00 (mid +12%).

Sarepta Therapeutics (SRPT)-26 Feb 25-2024 Q4 Earnings call transcript

Sarepta Therapeutics (SRPT)-6 Nov 24-2024 Q3 Earnings call transcript

Sarepta Therapeutics (SRPT)-7 Aug 24-2024 Q2 Earnings call transcript

Sarepta Therapeutics (SRPT)-1 May 24-2024 Q1 Earnings call transcript

- **Revenue milestone**: $1.14B full year net product revenue (36% YoY growth), driven by ELEVIDYS ($200M) and PMOs. 
- **Profitability achieved**: First GAAP profitable quarter in Q4 2023. 
- **Pipeline momentum**: ELEVIDYS BLA supplement accepted; SRP-5051 Phase III results positive; EMERGENE trial initiated. 
- **Manufacturing innovation**: Suspension process could reduce COGS by multiples; 2026 target for commercialization. 
- **Label expansion**: FDA review of broader ELEVIDYS access on track for June 2024 decision.

**【CEO Summary Section】**
- Q4 2023 total net product revenue: $365.1 million (55% YoY growth); Full year 2023 revenue: $1.14 billion (36% YoY growth). 
- ELEVIDYS net product revenue: $200 million for full year, $131.2 million Q4, despite label limited to 4-5 year olds (3% of Duchenne population). 
- Achieved GAAP profitability in Q4 2023; Ended year with $1.7 billion cash. 
- Submitted BLA supplement to expand ELEVIDYS label (remove age/ambulation restrictions) and transition to traditional approval. 
- 2024 goals: Broaden ELEVIDYS access, advance pipeline (SRP-5051, SRP-9003), and expand into external innovation.

**【CFO Financial Commentary】**
- Q4 2023 total revenue: $396.8 million (54% YoY growth). 
- Net product revenue: $365.1 million (ELEVIDYS: $131.2M, PMOs: $233.8M). 
- GAAP net income: $45.7 million; Non-GAAP net income: $86.6 million. 
- Cost of sales: $44.2 million (royalty expenses up due to ELEVIDYS sales). 
- R&D expenses: $195.5M (down 9% YoY); SG&A: $131.7M (up 11% YoY). 
- Cash position: $1.7 billion as of Dec 31, 2023.

**【R&D Pipeline Update】**
- ELEVIDYS BLA supplement accepted by FDA with PDUFA date June 21, 2024. 
- SRP-5051 (next-gen PMO) Part B results support NDA filing; Planning FDA meeting for accelerated approval. 
- EMERGENE Phase III trial for LGMD2E initiated; First patient dosed. 
- ENVISION trial for non-ambulatory Duchenne patients ongoing globally.

**【Q&A Highlights】**
- Label expansion: Science-driven request to remove age/ambulation restrictions; FDA review ongoing with June 21 PDUFA date. 
- Manufacturing: Catalent partnership stable despite Novo Nordisk acquisition; Suspension process development could reduce COGS by multiples. 
- COGS guidance: Targeting 80% gross margin, but expect erosion as heavier patients come online. 
- PMO franchise: 2023 growth of 12%+ with no cannibalization from ELEVIDYS. 
- LGMD2E trial: FDA supportive of totality of evidence approach; 15-patient EMERGENE study design agreed.

Actual											-0.23	-1.93	-2.5	-2.4	-2.1	-1.02	-0.6	-1.42	-1.2	-2.65	-2.94	-1.24	-5.86	-0.27	-0.46	0.47	0.37	0.07	0.34	1.5	-4.6	1.89	-1.8	-3.93
Forecast											-1.9169	-1.7248	-1.7112	-1.8005	-1.8279	-1.2983	-1.7865	-1.2551	-1.3129	-1.1084	-1.2243	-1.4738	-1.2934	-1.7768	-1.2231	0.0689	0.0129	-0.1295	-0.0755	1.8825	-3.207	0.8323	-0.727	-1.1972
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+88.00%	-11.90%	-46.10%	-33.30%	-14.89%	+21.44%	+66.41%	-13.14%	+8.60%	-139.08%	-140.14%	+15.86%	-353.07%	+84.80%	+62.39%	+582.15%	+2768.22%	+154.05%	+550.33%	-20.32%	-43.44%	+127.08%	-147.59%	-228.27%

SRPT

SRPT fundamentals

SRPT Q4 2025 Earnings

Earnings Call

You can ask Aime

SRPT

SRPT fundamentals

SRPT Q4 2025 Earnings

Earnings Call

SRPT Earnings Call Summary for Q4/20254:30 PM on Feb 25, 2026

SRPT Earnings Call Summary for Q3/20254:30 PM on Nov 3, 2025

SRPT Earnings Call Summary for Q2/2025 Mar 25, 2026

SRPT Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

SRPT Earnings Call Summary for Q4/20244:30 PM on Feb 26, 2025

You can ask Aime